CYRX (Cryoport, Inc.) Stock Financials & Earnings

CYRXCryoport, Inc.

Mkt Cap$408M

Revenue (TTM)$176M

Net Income (TTM)$73M

EPS (TTM)$1.40

Free Cash Flow (TTM)-$37M

Gross Margin47.1%

Op. Margin-20.9%

Net Margin41.2%

FCF Margin-21.1%

P/S Ratio (TTM)2.3x

P/E Ratio (TTM)5.6x

YoY Rev Growth-8.8%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$63M	$27M	-$10M
Q2 23	$57M	$25M	-$18M
Q3 23	$56M	$24M	-$17M
Q4 23	$57M	$23M	-$70M
Q1 24	$37M	$15M	-$18M
Q2 24	$40M	$18M	-$78M
Q3 24	$57M	$25M	-$16M
Q4 24	$60M	$27M	-$14M
Q1 25	$41M	$19M	-$9M
Q2 25	$45M	$21M	-$10M
Q3 25	$44M	$21M	-$10M
Q4 25	$45M	$22M	-$8M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Revenue Segments

Quarter	Animal Health	Biopharmaceutical	Reproductive Medicine	Product	Service
Q1 23	$9M	$51M	$3M	—	—
Q2 23	$8M	$47M	$3M	—	—
Q3 23	$7M	$47M	$2M	—	—
Q3 24	—	—	—	$17M	$39M
Q1 25	—	—	—	$18M	$23M
Q2 25	—	—	—	$21M	$24M
Q3 25	—	—	—	$20M	$24M
Q4 25	—	—	—	$20M	$25M

Revenue by Geography

Quarter	Americas	Asia Pacific (APAC)	Europe, the Middle East and Africa (EMEA)	Asia Pacific	Emea
Q1 23	$34M	$11M	$18M	—	—
Q2 23	$31M	$11M	$15M	—	—
Q3 23	$32M	$10M	$14M	—	—
Q3 24	$31M	—	—	$11M	$14M
Q1 25	$32M	—	—	$3M	$6M
Q2 25	$33M	—	—	$6M	$6M
Q3 25	$33M	—	—	$4M	$7M
Q4 25	$33M	—	—	$6M	$7M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$39M	$484M	$523M
Q2 23	$67M	$437M	$505M
Q3 23	$59M	$406M	$466M
Q4 23	$46M	$410M	$457M
Q1 24	$50M	$399M	$449M
Q2 24	$46M	$381M	$427M
Q3 24	$45M	$228M	$273M
Q4 24	$45M	$216M	$262M
Q1 25	$36M	$208M	$244M
Q2 25	$36M	$208M	$244M
Q3 25	$256M	$166M	$421M
Q4 25	$250M	$161M	$411M

Shares Outstanding

Revenue Per Employee

Revenue / Employee